CF
AMRX icon

Corebridge Financial’s Amneal Pharmaceuticals AMRX Stock Holding History

Corebridge Financial’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-77,957
Closed -$653K – 159
2025
Q1 		$653K Sell
77,957
-1,156
-1% -$9.65K ﹤0.01% 1452
2024
Q4 		$627K Sell
79,113
-5,971
-7% -$50.1K ﹤0.01% 1552
2024
Q3 		$708K Sell
85,084
-525
-0.6% -$4.11K ﹤0.01% 1544
2024
Q2 		$544K Buy
+85,609
New +$543K ﹤0.01% 1650

Other funds holding AMRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Corebridge Financial's AMRX Position: Q2 2025 in Review

Corebridge Financial sold out of Amneal Pharmaceuticals (AMRX) in Q2 2025, closing a stake of 77,957 shares — an estimated $653K sold.

Corebridge Financial first reported a position in AMRX in Q2 2024 and held it in 4 quarters. The position peaked at $708K in Q3 2024. 241 funds tracked by Wall St. Rank hold AMRX as of Q2 2025.

  • Corebridge Financial reported no remaining Amneal Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Corebridge Financial sold 77,957 Amneal Pharmaceuticals shares in Q2 2025, an estimated $653K.
  • Corebridge Financial first reported a position in Amneal Pharmaceuticals in Q2 2024 and held it in 4 quarters.
  • Corebridge Financial's Amneal Pharmaceuticals position peaked at $708K in Q3 2024.
  • 241 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q2 2025.

Based on Corebridge Financial's 13F filing for Q2 2025, filed 12 Aug 2025.